1. Home
  2. NKTR

as 05-30-2025 12:39pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Founded: 1990 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 160.4M IPO Year: 1994
Target Price: $4.92 AVG Volume (30 days): 1.8M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.63 EPS Growth: N/A
52 Week Low/High: $0.43 - $1.52 Next Earning Date: 05-08-2025
Revenue: $87,248,000 Revenue Growth: -3.24%
Revenue Growth (this year): -42.1% Revenue Growth (next year): -6.36%

NKTR Daily Stock ML Predictions

Share on Social Networks: